Highlights

  • Racura Oncology Limited (ASX: RAC) is taking its three-pronged oncology story to the 20th Bioshares Biotech Summit in Queenstown, New Zealand, on 6-7 August 2026.
  • Executive Chair Dr Peter Smith will present on Racura Oncology at 12:15PM on Friday 7 August 2026 and chair "Session 4: Improving Lifespan" from 4:30-5:45PM on Thursday 6 August 2026.
  • The company will also host an investor briefing in Auckland on 5 August 2026, ahead of the summit.
  • The three-pronged strategy spans a Phase 3 AML program, the HARNESS-1 Phase 1 trial and the CPACS Phase 1 program, all built around RC220.
  • Conference participation is investor outreach, not clinical validation, and Racura Oncology remains an early clinical-stage company carrying significant risk.

Racura Oncology Limited (ASX:RAC) is a clinical-stage biopharmaceutical company whose stated mission is to "silence cancer". In early August 2026 the company is stepping onto one of the region's better-known specialist biotech stages, the Bioshares Biotech Summit, to tell its story to an audience of dedicated life-sciences investors. For a company advancing a single lead compound across three separate cancer indications, a summit devoted entirely to biotechnology offers a natural venue to explain a strategy that can be hard to convey in a headline.

This article looks at what the Bioshares Biotech Summit is, the role Executive Chair Dr Peter Smith will play there, and how presenting a three-pronged oncology plan to a specialist investor crowd fits Racura Oncology's broader outreach. It does not comment on valuation or share price, nor forecast trial outcomes. The focus is on what has been announced and what it may, or may not, mean for followers of ASX: RAC.

Inside the Announcement

On 6 July 2026 Racura Oncology confirmed two connected pieces of investor engagement. The first is an investor briefing in Auckland, New Zealand, on Wednesday 5 August 2026. The event is a morning-tea briefing, arriving from 10:15AM for a 10:30AM start at a central Auckland location still to be confirmed, with all existing and potential shareholders invited and registration asked by Friday 10 July 2026 through [email protected]. The briefing is hosted by Executive Chair Dr Peter Smith, who is expected to outline Racura's strategy and the advancement of its lead formulation, RC220, across three major oncology indications, as well as the company's near-term catalyst schedule.

The second piece, and the centrepiece of this article, is Racura Oncology's participation in the 20th Bioshares Biotech Summit in Queenstown, New Zealand, on 6-7 August 2026. Dr Peter Smith will present on Racura Oncology at 12:15PM on Friday 7 August 2026 and chair "Session 4: Improving Lifespan" from 4:30-5:45PM on Thursday 6 August 2026. Meeting requests during the summit were directed to Jane Lowe at [email protected].

Taken together, the Auckland briefing and the Queenstown summit form a compact two-stop programme either side of the Tasman, giving Racura Oncology consecutive opportunities to reach New Zealand retail shareholders and a wider specialist investor base within the same week.

Background: Racura Oncology and RC220

To appreciate why a summit slot matters to Racura Oncology, it helps to understand what the company is trying to do. Racura describes itself as a Phase 3 clinical-stage biopharmaceutical company. Its lead asset is (E,E)-bisantrene, a small-molecule anticancer agent that primarily acts by binding to G-quadruplex (G4) structures in DNA and RNA, leading to potent silencing of MYC, or c-MYC, an important regulator of cancer growth. The company states that (E,E)-bisantrene has demonstrated therapeutic activity in cancer patients and has a well-characterised safety profile.

RC220 is Racura's proprietary formulation of (E,E)-bisantrene. Recent discoveries have enabled composition-of-matter intellectual property filings that the company says may provide up to 20 years of patent protection over (E,E)-bisantrene, though patent outcomes are never guaranteed. Racura is led by CEO and Managing Director Dr Daniel Tillett, with Dr Peter Smith as Executive Chair. The company works with collaborators including Astex, Emory University, Purdue University, MD Anderson, Sheba, the UNC School of Medicine, the University of Wollongong and the University of Newcastle, and says it is actively exploring partnerships, licence agreements and merger and acquisition opportunities to accelerate global access to RC220. Nothing on that front has been signed.

The "three-pronged" description refers to how RC220 is being tested. The first prong is a Phase 3 program in acute myeloid leukaemia (AML), where RC220 targets c-MYC silencing. The second is HARNESS-1, a Phase 1 trial combining RC220 with Tagrisso (osimertinib) in mutant EGFR (EGFRm) non-small cell lung cancer (NSCLC). The third is CPACS, a Phase 1 program pairing RC220 with doxorubicin in solid tumours, aiming at both cardioprotection and enhanced anticancer activity.

Why the Bioshares Stage Suits a Three-Pronged Story

A specialist audience for a specialist message

The Bioshares Biotech Summit is a long-running gathering focused on the biotechnology sector, and this year marks its 20th edition. Held in Queenstown, New Zealand, it draws an audience already fluent in the language of clinical trials, endpoints and pipelines. That matters for Racura Oncology because its investment case is not a single product with a single readout. It is one compound, RC220, deployed against three distinct cancer settings, each at a different stage and with its own rationale. Explaining that structure to a room of biotech specialists lets Dr Peter Smith go deeper without first justifying why oncology drug development takes years.

Presenting and chairing: two kinds of visibility

Dr Smith's involvement comes in two forms. The 12:15PM presentation on Friday 7 August 2026 is Racura's own platform, its chance to lay out the three-pronged strategy and near-term plans directly. Chairing "Session 4: Improving Lifespan" from 4:30-5:45PM on Thursday 6 August 2026 is different: as session chair, Dr Smith helps guide a broader thematic discussion rather than pitching Racura, giving the company a presence beyond its single speaking slot. That dual footprint is a form of profile-building a standard investor roadshow does not always deliver.

Outreach woven together, not stand-alone

The Bioshares appearance does not sit in isolation. It is paired with the Auckland briefing the day before, and meeting requests during the summit are being funnelled through investor-relations contact Jane Lowe. This suggests Racura is treating the trip as a coordinated exercise: a retail-friendly briefing in Auckland on 5 August, then a specialist-investor summit in Queenstown across 6-7 August, with one-on-one meetings around the formal sessions. Both events being held in New Zealand also signals where Racura is directing this effort, putting its Executive Chair in front of trans-Tasman audiences rather than a domestic Australian circuit.

What It Could Mean for ASX: RAC

For followers of ASX: RAC, the value of a summit appearance is communication rather than clinical progress. A well-received presentation can raise a company's profile, introduce its story to new investors, and give existing shareholders a clearer sense of management's priorities and timeline. Chairing a session adds visibility a simple exhibitor booth would not.

That said, the benefits are inherently soft and hard to measure. A conference slot does not change the underlying science, advance a trial by a single patient, or alter the regulatory path any of the three programs must follow. It is an opportunity to explain, not to prove. The most an investor can conclude is that Racura Oncology is actively engaging with the specialist investment community, and any effect on sentiment would depend on how the message is received.

Limitations and Key Risks

It is important to be clear about what conference participation is and is not. Presenting at, or chairing a session within, the Bioshares Biotech Summit is investor outreach. It is not a clinical result, a regulatory milestone or a financial outcome, and should not be read as validation of RC220 in any of its indications.

Racura Oncology carries the full spread of risks common to early clinical-stage biopharmaceutical companies. Clinical risk is significant: HARNESS-1 and CPACS are Phase 1 trials, and early-stage studies are designed chiefly to assess safety, not efficacy. Any safety signals to date do not prove that RC220 works or that it is safe in wider use, and even the Phase 3 AML program must still generate the data to support its objectives. Regulatory risk follows, because trial data must satisfy health authorities before any product can reach patients, with no guarantee of approval. Funding risk is ever-present, as running three oncology programs concurrently is capital-intensive. Execution risk spans patient recruitment, trial conduct and the demands of advancing multiple studies at once. Commercialisation risk remains, because the partnerships, licences and merger and acquisition possibilities Racura says it is exploring are exploratory only, with nothing signed. Investors should weigh these factors and treat a summit appearance as one small, non-clinical data point.

What Investors May Watch Next

In the immediate term, the practical items are the two events: the Auckland investor briefing on 5 August 2026 and Dr Peter Smith's presentation and session-chairing role at Bioshares on 6-7 August 2026. Shareholders can register for the Auckland briefing through the company's investor-relations email, or request a meeting during the summit via Jane Lowe.

Beyond the events, the more meaningful markers will be substantive. Dr Smith is expected to outline Racura's near-term catalyst schedule at the Auckland briefing, and that schedule, once articulated, gives investors concrete milestones to follow across the Phase 3 AML program, HARNESS-1 and CPACS. Progress in any of those trials, further conference or abstract acceptances, and partnership developments would each carry more weight than the outreach itself. For now, Bioshares is best seen as a step in how Racura Oncology communicates, with the real tests still lying in the clinic.

Conclusion

Racura Oncology's decision to take its three-pronged cancer strategy to the 20th Bioshares Biotech Summit places the company before an audience built to understand exactly the story it is telling: one molecule, RC220, tested across AML, EGFRm NSCLC and solid tumours. With Dr Peter Smith both presenting and chairing a session, and an Auckland briefing bookending the trip, ASX: RAC is making a deliberate, coordinated push to broaden its profile among specialist and retail investors alike. The appearance is a communication milestone rather than a clinical one, and changes nothing about the science or the risks of early-stage oncology development. What it does offer is a clearer window into how, and where, Racura Oncology intends to tell its story.